NCT02316106: Phase 2 - A Study to Evaluate 3 Dose Schedules of Daratumumab in SMM - CENTAURUS

CENTAURUS

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

The purpose of this study is to evaluate three daratumumab dose schedules in participants with Smoldering Multiple Myeloma.

Sponsor

Janssen Research & Development, LLC

Multiple Locations

International Study

---

ClinicalTrials.gov Identifier: NCT02316106

Official Title: A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma

First Posted : December 12, 2014

Click here to see details on ClinicalTrials.gov